110
Participants
Start Date
October 3, 2022
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
Atorvastatin 10mg
Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Placebo
Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Continuous Positive Airway Pressure Therapy
CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
RECRUITING
Columbia University Irving Medical Center, New York
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Columbia University
OTHER